Ellen Wei

883 total citations
26 papers, 664 citations indexed

About

Ellen Wei is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Ellen Wei has authored 26 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Hematology, 13 papers in Molecular Biology and 13 papers in Genetics. Recurrent topics in Ellen Wei's work include Chronic Lymphocytic Leukemia Research (12 papers), Multiple Myeloma Research and Treatments (9 papers) and Lymphoma Diagnosis and Treatment (7 papers). Ellen Wei is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Multiple Myeloma Research and Treatments (9 papers) and Lymphoma Diagnosis and Treatment (7 papers). Ellen Wei collaborates with scholars based in Canada, United States and New Zealand. Ellen Wei's co-authors include Suzanne Trudel, A. Keith Stewart, Zhihua Li, Hong Chang, Carla Heise, Christine Chen, Donna Reece, Marion Wiesmann, P. Leif Bergsagel and Vishal Kukreti and has published in prestigious journals such as Nature Communications, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Ellen Wei

24 papers receiving 648 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen Wei Canada 10 425 250 176 156 146 26 664
Zhihong Zeng United States 6 467 1.1× 203 0.8× 119 0.7× 111 0.7× 114 0.8× 13 652
Jennifer Lauchle United States 13 512 1.2× 243 1.0× 181 1.0× 203 1.3× 83 0.6× 23 833
Alberto Rocci Italy 14 417 1.0× 373 1.5× 99 0.6× 170 1.1× 53 0.4× 32 661
Pierre Sujobert France 12 453 1.1× 224 0.9× 313 1.8× 114 0.7× 118 0.8× 47 836
Maher Albitar United States 14 321 0.8× 305 1.2× 287 1.6× 213 1.4× 197 1.3× 48 783
Linda W. Horton United States 9 253 0.6× 118 0.5× 183 1.0× 239 1.5× 144 1.0× 12 595
Frédéric Gilles United States 12 375 0.9× 124 0.5× 202 1.1× 300 1.9× 353 2.4× 21 753
Anna Dolnik Germany 15 564 1.3× 333 1.3× 190 1.1× 151 1.0× 122 0.8× 39 900
Ya‐Huei Kuo United States 15 579 1.4× 357 1.4× 94 0.5× 235 1.5× 53 0.4× 44 930
Pratima Chaurasia United States 8 212 0.5× 155 0.6× 149 0.8× 84 0.5× 72 0.5× 16 463

Countries citing papers authored by Ellen Wei

Since Specialization
Citations

This map shows the geographic impact of Ellen Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Wei more than expected).

Fields of papers citing papers by Ellen Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Wei. The network helps show where Ellen Wei may publish in the future.

Co-authorship network of co-authors of Ellen Wei

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Wei. A scholar is included among the top collaborators of Ellen Wei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Wei. Ellen Wei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Eagles, Jenna, Arnavaz Danesh, Danielle Croucher, et al.. (2023). Cell-Free DNA from Blood or Bone Marrow as Alternatives to Bone Marrow Cells for Molecular Diagnostics and Monitoring of Multiple Myeloma. Blood. 142(Supplement 1). 4693–4693. 1 indexed citations
2.
Croucher, Danielle, Laura M. Richards, Daniel D. Waller, et al.. (2021). Longitudinal single-cell analysis of a myeloma mouse model identifies subclonal molecular programs associated with progression. Nature Communications. 12(1). 6322–6322. 20 indexed citations
3.
Chen, Christine I., Lisa W. Le, Ellen Wei, et al.. (2018). A phase 2 study of ofatumumab (Arzerra®) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL)*. Leukemia & lymphoma. 60(1). 92–100. 8 indexed citations
4.
Chen, Christine I., Lisa W. Le, Ellen Wei, et al.. (2018). A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL). Leukemia & lymphoma. 60(4). 980–989. 7 indexed citations
5.
6.
Chen, Christine, Lisa W. Le, Vishal Kukreti, et al.. (2012). Long-Term Follow-up of a Phase 2 Study of Single Agent Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL). Blood. 120(21). 718–718. 4 indexed citations
7.
Trudel, Suzanne, Sam Scanga, Fabrizio G. Mastronardi, et al.. (2012). GSK-3 Spatial Regulation Has an Essential Role in Lenalidomide Activity and Represents a Biomarker of Clinical Response in CLL. Blood. 120(21). 1793–1793. 3 indexed citations
8.
9.
Liang, Sheng-Ben, Young Trieu, Zhihua Li, et al.. (2011). Molecular Target Characterization and Antimyeloma Activity of the Novel, Insulin-like Growth Factor 1 Receptor Inhibitor, GTx-134. Clinical Cancer Research. 17(14). 4693–4704. 8 indexed citations
10.
Croucher, Danielle, Víctor H. Jiménez‐Zepeda, Brent D. G. Page, et al.. (2011). Abstract A201: The potent STAT3/5 inhibitor, BP-1–102, demonstrates significant antitumor activity against Waldenstrom macroglobulinemia.. Molecular Cancer Therapeutics. 10(11_Supplement). A201–A201. 1 indexed citations
11.
Chen, Christine I., P. Leif Bergsagel, Wei Xu, et al.. (2010). Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 29(9). 1175–1181. 109 indexed citations
12.
Chen, Christine, Wei Xu, Vishal Kukreti, et al.. (2008). A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL). Blood. 112(11). 44–44. 9 indexed citations
13.
Chen, Christine I., Joseph Brandwein, Vishal Kukreti, et al.. (2007). A Phase II Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL).. Blood. 110(11). 2042–2042. 28 indexed citations
14.
Masih‐Khan, Esther, Suzanne Trudel, Carla Heise, et al.. (2006). MIP-1α (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma. Blood. 108(10). 3465–3471. 54 indexed citations
15.
Masih‐Khan, Esther, Suzanne Trudel, Zhihua Li, et al.. (2005). Macrophage Inflammatory Protein (MIP)-1alpha (CCL3) Is a Downstream Target of FGFR3 and RAS Signaling in Multiple Myeloma.. Blood. 106(11). 251–251. 2 indexed citations
16.
Trudel, Suzanne, Zhihua Li, Ellen Wei, et al.. (2004). CHIR258, a Novel Multi-Targeted Tyrosine Kinase Inhibitor, for the Treatment of t(4;14) Multiple Myeloma.. Blood. 104(11). 641–641. 1 indexed citations
17.
Zhu, Yuan Xiao, Sally J. Benn, Zhihua Li, et al.. (2004). The SH3–SAM Adaptor HACS1 is Up-regulated in B Cell Activation Signaling Cascades. The Journal of Experimental Medicine. 200(6). 737–747. 45 indexed citations
18.
Trudel, Suzanne, Ellen Wei, Zhihua Li, et al.. (2004). Targeting FGFR3 in t(4;14) Mutiple Myeloma: Pre-Clinical Studies of PRO-001, a Novel Anti-FGFR3 Neutralizing Antibody.. Blood. 104(11). 2479–2479. 1 indexed citations
19.
Trudel, Suzanne, Zhihua Li, Ellen Wei, et al.. (2004). CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 105(7). 2941–2948. 223 indexed citations
20.
Wen, Xiao‐Yan, A. Keith Stewart, Jennifer Skaug, Ellen Wei, & Lap-Chee Tsui. (2001). Murine phosphatidylserine-specific phospholipase A1 (Ps-pla1) maps to Chromosome 16 but is distinct from the lpd (lipid defect) locus. Mammalian Genome. 12(2). 129–132. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhihong Zeng Breakdown of academic impact, for papers by Jennifer Lauchle Breakdown of academic impact, for papers by Alberto Rocci Breakdown of academic impact, for papers by Pierre Sujobert Breakdown of academic impact, for papers by Maher Albitar Breakdown of academic impact, for papers by Linda W. Horton Breakdown of academic impact, for papers by Frédéric Gilles Breakdown of academic impact, for papers by Anna Dolnik Breakdown of academic impact, for papers by Ya‐Huei Kuo Breakdown of academic impact, for papers by Pratima Chaurasia
Rankless by CCL
2026